The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,024.00
Bid: 12,024.00
Ask: 12,028.00
Change: 36.00 (0.30%)
Spread: 4.00 (0.033%)
Open: 12,254.00
High: 12,256.00
Low: 12,018.00
Prev. Close: 11,988.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

WRAPUP 1-Euro zone economies' plucky Q4 belies troubled growth outlook

Fri, 29th Jan 2021 11:37

* Germany and Spain eke out narrow Q4 growth

* France contracts by less than expected

* But vaccine roll-out issues, restrictions blight outlook

* IMF sees euro zone recovery lagging U.S., Japan

By Paul Carrel and Leigh Thomas

BERLIN/PARIS, Jan 29 (Reuters) - Growth in Germany and Spain
and a smaller-than-expected contraction in France pointed to
resilience in the euro zone economy in the final three months of
last year, but the bright spot belies a more troubled outlook
for the bloc.

In Germany, robust exports helped Europe's largest economy
eke out 0.1% growth in the fourth quarter, staving off
contraction despite a second wave of the new coronavirus
slamming the brakes on consumption, data showed on Friday.

France, the euro zone's second-largest economy, shrank 1.3%
in the final three months of 2020 after the country entered a
second coronavirus lockdown in October to contain a second wave
of infections.

Spain achieved timid quarterly growth of 0.4%. But that has
not stopped Spain from recording its worst-ever annual economic
contraction, with output falling 11% from 2019's level, official
data showed.

"Numbers for Germany, France and Spain showed that GDP was
relatively resilient in Q4," Nicola Nobile at Oxford Economics
wrote in a research note. But he added, "there are not many
indications that this dynamic could have continued in Q1."

"All in all, the disappointing vaccine roll-out so far, the
extension of restrictions in many European countries and the
latest data now point to continued weakness in the eurozone over
the coming months."

The French slump, which followed an 18.5% rebound in the
third quarter after a first lockdown, beat expectations for a 4%
contraction on average in a Reuters poll of 28 economists,
surpassing even the highest estimate of -1.4%.

But France is on tenterhooks to find out in the coming days
whether the government will put the country under a new lockdown
and in particular whether schools will be closed.

In Germany, Chancellor Angela Merkel and state leaders
agreed last week to extend a lockdown until mid-February as the
country, once a role model for fighting the pandemic, struggles
with a second wave and record daily numbers of COVID-19 deaths.

On Wednesday, German government slashed its growth forecast
to 3% this year, a sharp revision from last autumn's estimate of
4.4%, caused by a second coronavirus lockdown.

TRAILING U.S.

The economic outlook across the 19-country euro zone is
being muddied by a row between the European Union and
Anglo-Swedish firm AstraZeneca over its supply of
vaccines to the bloc, and by the return of inflation in Germany.

The International Monetary Fund said this week the euro area
is likely to slip behind the United States in its recovery.

"Recovery paths vary within the group, with the U.S. and
Japan projected to regain end-2019 activity levels in the second
half of 2021, while in the euro area and the United Kingdom
activity is expected to remain below end-2019 levels into 2022,"
the IMF said in its in its World Economic Outlook.

The AstraZeneca supply issue is a blow to Europe's COVID-19
vaccination drive, and the German inflation spike - consumer
prices turned positive and rose in January to 1.6% on the year -
adds to a complex mix of data for the European Central Bank to
assess.

ECB data released on Friday showed lending to euro zone
companies picked up last month though the bloc was probably back
in recession and banks said they were tightening access to
credit amid fear of defaults amid a fresh wave of lockdowns.

The ECB is unlikely to cut its already-record-low policy
because that would do little to revive the pandemic-hit euro
zone economy, five sources told Reuters, playing down concern
about a strong euro.

Traders were left scratching their head this week when Dutch
central bank governor Klaas Knot said the ECB "had room" to push
its Deposit Facility Rate, currently at minus 0.5%, further
below zero if needed to stem a rally in the euro EUR=.

The sources said Knot had raised the rate cut issue at the
ECB's policy meeting last week but the discussion was "marginal"
and not considered part of the ECB's policy strategy, which is
now focussed on bond purchases and cheap loans to banks.

"ECB communication could be such a powerful tool but is
really very confusing," BofA analysts said in a research note.

(Additional reporting by Belén Carreño and Joao Manuel Vicente
Mauricio in Madrid and by Francesco Canepa, Balazs Koranyi and
Frank Siebelt in Frankfurt; editing by Larry King)

More News
11 Apr 2024 08:54

LONDON MARKET OPEN: European markets mixed ahead of ECB decision

(Alliance News) - European equities lacked direction early Thursday morning, ahead of an interest rate decision from the European Central Bank this afternoon.

Read more
11 Apr 2024 07:49

LONDON BRIEFING: Astra promises dividend hike; Darktrace ups guidance

(Alliance News) - Stocks in London are called to open slightly higher on Thursday, as investors eye the latest interest rate decision from the European Central Bank, a day after a hotter-than-expected US inflation reading.

Read more
11 Apr 2024 07:20

AstraZeneca to hike 2024 dividend by 7%

(Sharecast News) - Biopharma giant AstraZeneca has announced that it will increase its annual dividend by 7%, which the board said demonstrates its confidence in the company's performance and cash generation.

Read more
8 Apr 2024 08:36

TOP NEWS: AstraZeneca hails neurological data for Ultomiris, Soliris

(Alliance News) - AstraZeneca PLC on Monday said long-term data in generalised myasthenia gravis will underscore the "vital role" of its Ultomiris and Soliris antibodies in the treatment landscape.

Read more
8 Apr 2024 07:43

LONDON BRIEFING: Astra hails neurology data; CVS flags cyberattack

(Alliance News) - London's FTSE 100 is called to open a touch higher on Monday, ahead of an interest rate decision in the eurozone and a US inflation reading later in the week.

Read more
8 Apr 2024 07:02

AstraZeneca's Enhurtu cancer gets US green light for adult patients

(Sharecast News) - AstraZeneca and Daiichi Sankyo's Enhertu cancer drug has been approved in the US for adult patients with unresectable or metastatic solid tumours who have received prior systemic treatment and have no satisfactory alternative options.

Read more
8 Apr 2024 06:53

TOP NEWS: AstraZeneca's, Daiichi's Enhertu receives US FDA approval

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Saturday announced that the US Food & Drug Administration has approved their cancer drug conjugate for patients with metastatic HER2-positive solid tumours.

Read more
5 Apr 2024 09:42

AstraZeneca makes "breakthrough" in treating small cell lung cancer

(Alliance News) - AstraZeneca PLC on Friday reported positive results relating to its Imfinzi cancer treatment in phase III trials.

Read more
5 Apr 2024 07:50

LONDON BRIEFING: Shell to book USD600 million first-quarter write-off

(Alliance News) - London's FTSE 100 is called to open lower on Friday, with hawkish remarks from Federal Reserve policymakers and fears of ratcheting Middle East tensions giving investors little to cheer about ahead of the latest US jobs data.

Read more
5 Apr 2024 07:23

AstraZeneca announces positive lung cancer treatment trial results

(Sharecast News) - AstraZeneca announced positive high-level results from a phase three trial demonstrating significant advancements in the treatment of limited-stage small cell lung cancer (LS-SCLC) on Friday.

Read more
4 Apr 2024 13:09

UK shareholder meetings calendar - next 7 days

Friday 5 April 
Faron Pharmaceuticals LtdAGM
VPC Specialty Lending Investments PLCGM re capital return via B share scheme
Monday 8 April 
Premier African Minerals LtdAGM
Tuesday 9 April 
Ethernity Networks LtdEGM re board appointments and option grants
Wednesday 10 April 
Valereum PLCAGM
Wincanton PLCGM re takeover by GXO Logistics Inc
Thursday 11 April 
AstraZeneca PLCAGM
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
3 Apr 2024 22:01

Biden, Senator Bernie Sanders push companies to cut cost of asthma inhalers, prescription drugs

WASHINGTON, April 3 (Reuters) - President Joe Biden hosted a White House event with U.S. Senator Bernie Sanders on Wednesday to tout their fight against high prescription drug prices and push companies to cut the cost of inhalers for asthma sufferers.

Read more
3 Apr 2024 17:22

UK's FTSE 100 pressured by stronger pound; miners climb

FTSE 100 flat, FTSE 250 up 0.2%

*

Read more
3 Apr 2024 11:02

CORRECT: AstraZeneca, Daiichi make US progress with licence approvals

(Correcting the description of extravascular haemolysis' effects on patients with paroxysmal nocturnal haemoglobinuria)

Read more
2 Apr 2024 15:22

London close: Stocks turn red on return from Easter break

(Sharecast News) - UK stocks experienced a downturn by the end of trading on Tuesday, as investors resumed activity following the extended weekend, with initial gains reversed by the close ahead of a week marked by a number of key economic data releases.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.